Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
Mallinckrodt
Dow
Johnson and Johnson
Harvard Business School

Last Updated: October 19, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Cadazolid

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug Cadazolid: Patents, clinical trial progress, indications

Cadazolid is an investigational drug.

There have been 5 clinical trials for Cadazolid. The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2013.

The most common disease conditions in clinical trials are Diarrhea, Communicable Diseases, and Infection. The leading clinical trial sponsors are Actelion and [disabled in preview].

There are three US patents protecting this investigational drug and seventy-six international patents.

Recent Clinical Trials for Cadazolid
TitleSponsorPhase
Comparison of Cadazolid Versus Vancomycin in Children With Clostridium Difficile-associated Diarrhea (CDAD)ActelionPhase 2/Phase 3
Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated DiarrheaActelionPhase 3
Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated DiarrheaActelionPhase 3

See all Cadazolid clinical trials

Clinical Trial Summary for Cadazolid

Top disease conditions for Cadazolid
Top clinical trial sponsors for Cadazolid

See all Cadazolid clinical trials

US Patents for Cadazolid

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Cadazolid   Start Trial Crystalline forms of cadazolid   Start Trial
Cadazolid   Start Trial 5-hydroxymethyl-oxazolidin-2-one-derivatives and their uses as antibacterials Actelion Pharmaceuticals Ltd. (Allschwil, CH)   Start Trial
Cadazolid   Start Trial Combination therapy comprising oxazolidinone-quinolones for use in treating bacterial infections Morphochem Aktiengesellschaft Fur Kombinatorishe Chemie (Munchen, DE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Cadazolid

Drugname Country Document Number Estimated Expiration Related US Patent
Cadazolid Argentina 063788 2026-11-10   Start Trial
Cadazolid Argentina 071762 2026-11-10   Start Trial
Cadazolid Austria 544764 2026-11-10   Start Trial
Cadazolid Australia 2007318901 2026-11-10   Start Trial
Cadazolid Australia 2009245351 2026-11-10   Start Trial
Cadazolid Brazil PI0718862 2026-11-10   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Medtronic
Moodys
Express Scripts
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.